Amlodipine in the current management of hypertension

J Clin Hypertens (Greenwich). 2023 Sep;25(9):801-807. doi: 10.1111/jch.14709. Epub 2023 Aug 7.


Hypertension is the leading cause of death worldwide, affecting 1.4 billion people. Treatment options include the widely used calcium channel blockers, among which amlodipine, a dihydropyridine, has unique characteristics that distinguish it from other drugs within this class. This review aims to provide an updated overview of the evidence supporting the use of amlodipine over the past 30 years and highlights its cardiovascular benefits in current hypertension management. Amlodipine has low renal clearance (7 mL/min/mg) and long half-life (35-50 h) and duration of action, which allows it to sustain its anti-hypertensive effect for more than 24 h following a single dose. Additionally, blood pressure (BP) control is maintained even when a dose has been missed, providing continuous protection in case of incidental noncompliance. It has proven to reduce BP variability and successfully lower BP. Amlodipine also controls BP in patients with a systolic/diastolic BP of 130/80 mm Hg or higher, diabetes, or chronic kidney disease without worsening glycemic or kidney function. Additionally, amlodipine is a wise choice for older adults due to its ability to control BP and protect against stroke and myocardial infarction. Side effects of amlodipine include edema, palpitations, dizziness, and flushing, which are more common with the higher dose of 10 mg. Amlodipine is cost effective and predicted to be cost saving when compared with usual care.

Keywords: amlodipine; blood pressure variability; calcium channel blockers; hypertension.

Publication types

  • Review

MeSH terms

  • Aged
  • Amlodipine* / adverse effects
  • Antihypertensive Agents / adverse effects
  • Blood Pressure
  • Calcium Channel Blockers / adverse effects
  • Humans
  • Hypertension*


  • Amlodipine
  • Antihypertensive Agents
  • Calcium Channel Blockers